Jazz Pharmaceuticals PLC at JPMorgan Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Great. Thanks, Bruce. We'll just give it a second for the video of the other members of the management team to pop up. And again, just a reminder

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Great. What about the -- you touched on kind of the suite of services as coverage kind of comes online. And one of the questions that we're getting is kind of how to interpret near-term oxybate revenue numbers while you've got this switch dynamic happening that may be either a drag on gross-to-nets or involve free bottles. So can you kind of maybe lay out kind of what the key metrics you think are best for investors to focus on? And whether or not -- and maybe address just this question of whether or not folks should be concerned about maybe a kind of optically lower revenue number in the short term as this switch proceeds?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Great. So thank you for asking questions. We've got a bunch of questions coming through on the portal. I'm just going to couple some that are similar to one another. One is, can you give any kind of number on conversion and the other one sort of read similar is what percentage of oxybate franchise patients are on Xywav?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Got it. Maybe just continuing the list of investor questions here. Is 50% conversion to Xywav the max you can achieve before triggering authorized generic entry?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. I think you maybe touched on this a little in the presentation, but kind of framed it little bit differently. So going forward, what is Jazz's main focus when it comes to use of free cash flow, the continued acquisitions, debt repayment? Could a dividend be down the road?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. A couple questions on Zepzelca. What are your plans for a confirmatory study following the ATLANTIS outcome?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Got it. And then another on Zepzelca here. You've talked about maybe a bolus of later line patients being treated in addition to second line patients with some eventual kind of washing out of those later line patients as the product becomes more established in second line, where are we in that process?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Got it. You're investing behind multiple new product launches right now coupled with some increased R&D investment, and that's led to operating margin contraction in recent years. Just looking ahead, how should investors think about the operating margin trajectory over kind of the near to medium term?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Maybe coming back to the oxybate franchise. Do you expect either revenue growth or volume growth for that business in 2021?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Thinking about JZP-458, how are you envisioning the potential ramp when that product comes to market and you kind of transition away from marketing Erwinaze?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Thank you. It looks like we're just about out of time here, so we'll wrap it up there. But thanks, everyone, for tuning in, and thanks team for joining us.